Inclusion Criteria:  Patients with hypopituitarism (HYPO) (>1 pituitary hormone deficiency) and stable hormone replacement for the prior three months At least one clinical sign of hypothalamic damage Female participants will be done in the early to midfollicular phase  Exclusion Criteria:  uncorrected hormone deficiency creatinine >1.5mg/dL alanine aminotransferase (ALT) or aspartate amino transferase (AST) >2.5x upper limit of normal hematocrit less than 30% suicidality or active psychosis participation in a trial with investigational drugs within 30 days using a high glucocorticoid dose Any type of diabetes mellitus Obese patients on GLP1-RA therapies vigorous physical exercise alcohol intake within 24 hours before the study participation evidence of any acute illness or any illness that the Investigator determines could interfere with study participation or safety pregnancy or breastfeeding for last 8 weeks known allergies towards GLP1-RA patients refusing or unable to give written informed consent Additionally for healthy controls: the presence of brain or pituitary tumor, radiation involving the hypothalamus or pituitary, history of hypopituitarism or receiving testosterone or glucocorticoids esters.